About Us
About Us

4th Dimension Bioprocess is the only US-based Contract Manufacturing and Development Services company (CDMO) exclusively focused on continuous bioprocessing. Founded in the Boston area in 2019,  the company is  built from the ground up with a new perspective and operational mindset from day 1:  to offer outsourced drug development services specially designed for continuous bioprocessing.


Our mission is to provide access to high quality, efficient, continuous manufacturing platforms to speed new biopharmaceutical therapies to the clinic.  Our automated and streamlined processes use continuous production lines rather than batch-based processes along with extensive automation, fully digital operations and integrated quality, analytics and release testing to speed your project from development to the clinic using an end to end continuous process.


We are a group of industry veterans who believe our industry is ready for a manufacturing revolution. We also appreciate the many obstacles to embracing change and the necessity to alleviate risk. Our team has supported over 20 successful INDs and BLAs and many continuous process implementation and evaluation projects. We have been founders, co-founders and senior managers in service, biotools and Biotech companies and have demonstrated a track record of successfully leading and managing businesses.

Lynne Frick


Lynne has managed multiple start-up service and technology companies and has held various corporate and business development positions. Throughout her career, she has consulted to and worked for technology providers, CDMOs and biotechnology companies in biomanufacturing, drug development and cell therapy. As the founder of BioGuides LLC, she set strategies for business development activities for early stage life sciences companies. She has consulted to many entrepreneurs to advance innovative, emerging products and technologies and to assist with technology adoption challenges and commercialization strategy. Her most recent corporate role was Director of Continuous Bioprocessing, the Americas, for Pall Corporation, after completing the asset sales of Tarpon’s BioSMB continuous chromatography technology to Pall.  She was VP of Business Development at Tarpon Biosystems for seven years. For five years, she was the Sr. Director of sales and marketing for a contract develomment and manufacturing company.  At Phylogix, a biotechnology company developing a chemoprotectant agent, she managed the outsourced manufacturing of a complex natural product-derived  protein. Early in her career, she held positons in executive sales and marketing at PerSeptive Biosystems and Millipore/Waters Corporation.

Tom Ransohoff​


Thomas C. Ransohoff, M.S., a Managing Director at BDO USA, LLP’s BioProcess Technology Group, has over 30 years of experience in the biopharmaceutical industry. Mr. Ransohoff’s areas of expertise include development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures. Mr. Ransohoff is a co-founder of Tarpon Biosystems, Inc and of BioFlash Partners LLC, where he was President and CEO prior to the successful sale of BioFlash in 2010. He joined BDO through acquisition of BioProcess Technology Consultants, Inc. (BPTC), where he had consulted for 17 years, most recently as Vice President and Principal Consultant. Before joining BPTC, Mr. Ransohoff held positions of Vice President, Operations at TranXenoGen, Inc., Vice President of Bioseparations at Dyax Corp and Senior Director Manufacturing, responsible for cGMP pilot plant operations at Repligen.

He is a member of the Editorial Advisory Board of BioPharm Magazine and has served on a number of scientific and professional advisory boards. Mr. Ransohoff has a Bachelor’s degree from MIT and a Master’s degree from the University of California, Berkeley, both in Chemical Engineering.

Peter Rock


Mr. Rock has over 28 years of financial management and operations experience with a variety of large industrial companies including United Technologies, Avery-Dennison and Schneider Electric. For the last 20 years, he has focused on life science and early stage tech companies, providing companies with financial guidance in fundraising, business models and financing advice. As Chief Financial Officer at Etiometry Inc., a predictive analytics company in healthcare, he raised over $13M in debt and equity financings for the company. He was VP of Finance for Dyax Corporation, leading the company to a successful IPO in 2000. As a contract CFO for early stage technology and life science companies, Mr. Rock has helped raise over $45 million in private financings and successfully sold 3 businesses for his clients including the 2015 sale of Tarpon Biosystems’ assets in single use continuous chromatography to Pall Corporation. He chaired the Massachusetts Biotechnology Council’s finance committee and the Business Solutions Advisory Board for the Biotechnology Industry Organization (BIO). Mr. Rock received a BBA from University of Massachusetts – Amherst and an MBA from Rensselaer Polytechnic Institute.

Greg Zarbis-Papastoitsis

Scientific Advisor

Dr. Greg Zarbis-Papastoitsis is the EVP of Process and Manufacturing sciences at Ankyra Therapeutics, an immuno-oncology company. He was the EVP of Process and Manufacturing at Compass Therapeutics managing all CMC functions. While at Compass he lead the development of an anti-CD137 antibody, filed its first IND in februaray 2019 and is currently in Phase 1 clinical trials for solid tumors. Previously he was the SVP of Process and Manufacturing Sciences at Eleven Biotherapeutics. Greg has deep experience managing outsourced GMP Bulk Drug Substance and Drug Product manufacturing activities and process and analytical validation efforts in preparation of a BLA filing.

Prior to Eleven he was the Senior Director of Downstream and Analytical Development at PERCIVIA, LLC, developing platform technologies for proteins produced with the PER.C6® human cell line. Previously he was Associate Director of Process and Analytical Development at Syntonix Pharmaceuticals, responsible for the early clinical development of a long lasting Factor IX (ALPROLIX®). Before Syntonix Dr. Zarbis-Papastoitsis worked on the commercial process of HUMIRA® (Abbott/Abbvie), and the purification development of IL2-Diptheria Toxin, ONTAK® (Seragen). He received a Ph.D. in Biology at Binghamton University followed by 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer disease. Dr. Zarbis-Papastoitsis has worked and /or evaluated clinical and commercial CDMO organizations such as Lonza, FUJI Diosynth, Cytovance, KBI, WuXi Biologics, Patheon, LSNE, Berkshire Sterile, Catalent among others.

Our Philosophy

We are first and foremost a service company. We are problem solvers with a passion for helping our industry fully adopt production line thinking and fully integrated manufacturing. It will not always be easy, but we will strive to make things easy for our customers. Our core values are reflected in our business philosophy; we are helpful, engaged, respectful and well prepared. We will partner with our customers to meet their timelines as we move together towards the future of biomanufacturing.

Get In Touch

For more information on our CDMO services, Pre-CDMO development services, continuous bioprocessing assessment or strategic partnership and investment opportunities, contact us directly below. Click Here for more information about our 4D Sandbox.

Scroll to Top